Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqCM:NKTR
NasdaqCM:NKTRPharmaceuticals

Will REZOLVE-AA Class Actions Over Trial Disclosures Change Nektar Therapeutics' (NKTR) REZPEG Narrative?

Nektar Therapeutics recently faced multiple securities class action filings and investigations alleging misleading disclosures around enrollment protocols and outcomes in its REZOLVE-AA Phase 2b trial, which previously failed to reach statistical significance. These legal challenges focus on whether management accurately represented the integrity of a key clinical program, raising fresh questions about governance, disclosure practices, and oversight of trial execution. We’ll now examine how...
NYSE:HCI
NYSE:HCIInsurance

Assessing HCI Group (HCI) Valuation After Mixed Near‑Term Returns And Strong Longer‑Term Gains

Recent performance snapshot for HCI Group stock Without a specific news announcement driving the move, HCI Group (HCI) has been trading with mixed returns recently, including a 3.3% decline over the past week and a small gain over the past month. See our latest analysis for HCI Group. That recent 1-week share price return of negative 5.7% sits against a year-to-date share price return of negative 10.9%. At the same time, the 1-year total shareholder return of 23.7% and 3-year total...
NasdaqGS:CYTK
NasdaqGS:CYTKBiotechs

A Look At Cytokinetics (CYTK) Valuation After Analyst Updates And Myqorzo Launch

Recent analyst updates following Cytokinetics (CYTK) fourth quarter results and the launch of its heart drug Myqorzo have put fresh attention on the stock as investors reassess the company’s long term prospects. See our latest analysis for Cytokinetics. Those fourth quarter numbers, the Myqorzo launch and the recent shelf registration filing have all come against a backdrop of relatively steady trading, with a 1 day share price return of 3.33% and a much stronger 1 year total shareholder...
NYSE:HR
NYSE:HRHealth Care REITs

A Look At Healthcare Realty Trust’s Valuation As Earnings Beat And Insider Buying Lift Optimism

Insider buying, earnings surprise and auditor change put Healthcare Realty Trust in focus Healthcare Realty Trust (HR) has drawn fresh attention after a Q4 2025 earnings beat coincided with insider share purchases by senior leaders and an auditor switch to Deloitte & Touche LLP. See our latest analysis for Healthcare Realty Trust. The share price has started to reflect this improving narrative, with an 8.9% 1 month share price return and 7.7% 3 month share price return helping lift the 1 year...
NYSE:TPC
NYSE:TPCConstruction

A Look At Tutor Perini (TPC) Valuation As CEO Share Buying Follows Turnaround Results

Why the latest CEO share purchase matters for Tutor Perini (TPC) The fresh insider buying by Tutor Perini (TPC) CEO, following a turnaround year in profitability, puts extra attention on the stock as investors weigh new earnings guidance and a recently affirmed quarterly dividend. See our latest analysis for Tutor Perini. After a sharp run that has produced a very large 3 year total shareholder return of more than 9x, recent trading has cooled, with a 30 day share price return of 13.7% and a...
NYSE:ACHR
NYSE:ACHRAerospace & Defense

Archer Aviation’s Valuation After FAA Means Of Compliance Milestone And Recent Share Price Weakness

Archer Aviation (ACHR) has just cleared a key regulatory hurdle, receiving final FAA acceptance of 100% of its Means of Compliance. This milestone moves its eVTOL ambitions closer to potential commercial operations. See our latest analysis for Archer Aviation. Despite the FAA milestone and recent news around earnings, conference appearances, and fresh equity financing, Archer Aviation’s share price return has been weaker in the short term. The stock has shown a 16.8% 7 day share price decline...
OB:LSG
OB:LSGFood

Will Lerøy’s Weaker 2025 Profits and Steady Dividend Payout Change Lerøy Seafood Group's (OB:LSG) Narrative

In February 2026, Lerøy Seafood Group ASA reported fourth-quarter 2025 sales of NOK 8,831.58 million and net income of NOK 175.14 million, alongside full-year 2025 sales of NOK 34,363.83 million and net income of NOK 365.96 million, and confirmed an annual dividend of NOK 2.50 per share. The sharp drop in profitability compared with the prior year, despite higher revenue and a maintained dividend, raises questions about the quality and resilience of Lerøy’s earnings mix. We’ll now examine...
CPSE:MAERSK B
CPSE:MAERSK BShipping

Does Maersk’s Middle East Service Suspension Reshape The Bull Case For A.P. Møller - Mærsk (CPSE:MAERSK B)?

A.P. Møller - Mærsk recently suspended key container services linking the Middle East with Europe and Asia, along with Gulf shuttle operations, and altered its ME1 rotation to bypass Jebel Ali as it responds to heightened security risks in the region. This shift reroutes cargo away from a major Middle Eastern hub, potentially reshaping how global shippers manage transit times, capacity, and supply chain resilience across these trade lanes. We’ll now examine how this temporary suspension of...
OM:EKTA B
OM:EKTA BMedical Equipment

Did Elekta's (OM:EKTA B) Sharp Q3 Earnings Slide Just Shift Its Investment Narrative?

Elekta AB (publ) has reported past third-quarter 2026 results showing sales of SEK 4,239 million and net income of SEK 10 million, sharply lower than the same period a year earlier, with basic earnings per share from continuing operations at SEK 0.03 versus SEK 0.89. Across the first nine months, the drop in sales to SEK 11,955 million and net income to SEK 346 million suggests meaningful pressure on Elekta’s profitability despite its established position in cancer treatment technology. Now...
NasdaqGS:WIX
NasdaqGS:WIXIT

Is Wixcom (WIX) Still Attractive After Recent 29% Weekly Share Price Jump

If you are wondering whether Wix.com at around US$93.89 is a bargain or just fairly priced, you are not alone, and this article is built to help you assess that question calmly and clearly. The stock has seen sharp swings recently, with a 29.4% return over the last 7 days and 24.5% over the last 30 days, set against a 7.0% decline year to date and a 44.9% decline over the past year, plus a 68.8% decline across 5 years and a 9.0% return over 3 years. These moves have put Wix.com back on many...
NasdaqGS:TENB
NasdaqGS:TENBSoftware

Is Tenable (TENB) Balancing Employee Ownership And Slowing Growth In Its Cybersecurity Strategy?

In late February, Tenable Holdings filed a US$135.12 million shelf registration related to 7,699,248 shares for an employee stock ownership plan, and earlier analyst commentary highlighted both its strong position in vulnerability management and rising competitive and demand concerns. While Tenable is presenting at the 3rd Billington State and Local CyberSecurity Summit today in Washington, D.C., investor focus is increasingly on how weak billings, slowing projected revenue growth, and flat...
NasdaqGS:IPAR
NasdaqGS:IPARPersonal Products

How Interparfums’ (IPAR) Delayed 10-K Amid Steady Dividend and Guidance Has Changed Its Investment Story

In early March 2026, Interparfums, Inc. disclosed that it would not meet the SEC deadline for filing its next Form 10-K, even as it recently reported full-year 2025 sales of US$1.49 billion and net income of US$168.39 million. This filing delay comes shortly after the Board reaffirmed an unchanged annual dividend of US$3.20 per share and maintained 2026 sales and EPS guidance, creating a contrast between steady capital returns and heightened reporting uncertainty. We’ll now examine how the...
NYSE:ARE
NYSE:AREHealth Care REITs

Does Alexandria Real Estate Equities' (ARE) Steady Dividend Signal Prudent Defense or Underused Balance Sheet Strength?

Alexandria Real Estate Equities’ board previously declared a quarterly cash dividend of US$0.72 per share for Q1 2026, payable April 15 to stockholders of record on March 31, matching the prior quarter and implying a 5.2% yield at the February 26, 2026 closing price. This steady payout, supported by a 33% dividend-to-funds-from-operations ratio, highlights management’s focus on reinforcing the balance sheet and preserving liquidity while offering income to shareholders. With this dividend...
ENXTAM:BESI
ENXTAM:BESISemiconductor

A Look At BE Semiconductor Industries (ENXTAM:BESI) Valuation After Hybrid Bonding Adoption Concerns

BE Semiconductor Industries (ENXTAM:BESI) has come under pressure after a report suggested that memory chipmakers such as Samsung Electronics and SK Hynix may delay adopting its hybrid bonding technology for high bandwidth memory, triggering a sharp intraday share price drop. See our latest analysis for BE Semiconductor Industries. Those hybrid bonding worries sit alongside a mixed price pattern, with a 6.4% 1 day share price return after the selloff, a 7 day share price return of negative...
ENXTAM:KPN
ENXTAM:KPNTelecom

Assessing KPN (ENXTAM:KPN) Valuation After New RCS Partnership With Twilio And Google

KPN’s RCS partnership and why it matters for shareholders Koninklijke KPN (ENXTAM:KPN) is in focus after Twilio announced a partnership with KPN and Google to roll out nationwide Rich Communication Services, or RCS, business messaging across Dutch mobile operators. See our latest analysis for Koninklijke KPN. The RCS announcement comes at a time when Koninklijke KPN’s share price, at €4.747, has a 30-day share price return of 6.03% and a 90-day share price return of 21.84%. Its 1-year total...
NYSE:GHC
NYSE:GHCConsumer Services

Assessing Graham Holdings (GHC) Valuation After Expansion In Healthcare And Education

Event driven snapshot on Graham Holdings (GHC) Recent news around Graham Holdings (GHC) centers on expansion in healthcare and education, including the acquisition of Covenant Home Health in Eastern Pennsylvania and new program partnerships through its Kaplan subsidiary. See our latest analysis for Graham Holdings. Recent earnings and impairment charges, along with the confirmed dividend, have come alongside a 1-year total shareholder return of 18.24%. A 30-day share price return of a 7.73%...
NasdaqGS:UMBF
NasdaqGS:UMBFBanks

Is Zacks’ Upgrade Amid Credit Jitters Altering The Investment Case For UMB Financial (UMBF)?

In recent days, UMB Financial was upgraded to a Zacks Rank #1 (Strong Buy) on the back of steadily rising earnings estimates, even as investors reassessed regional banks’ exposure to private credit risks following a peer’s sizeable loan write-off. This mix of improving analyst sentiment and heightened concern about credit quality highlights how differently market participants are weighing UMB Financial’s earnings outlook versus sector risk. Next, we’ll examine how the Zacks Rank upgrade and...
NYSE:LYB
NYSE:LYBChemicals

LyondellBasell Industries (LYB) Is Up 15.4% After Upgrade On Iran-Linked Supply Risks And Dividend Cut – Has The Bull Case Changed?

In early March 2026, KeyBanc Capital Markets upgraded LyondellBasell Industries, pointing to potential benefits from tighter global polyethylene supply amid the Iran conflict and higher crude-linked commodity margins. This upgrade comes shortly after LyondellBasell reduced its first-quarter dividend to conserve cash during one of the chemicals sector’s longest downturns, signaling a focus on financial resilience. Next, we’ll examine how the Iran-related polyethylene supply concerns and...
NYSE:FUN
NYSE:FUNHospitality

Six Flags Park Sale Refocuses Debt Laden Business On Core Assets

Six Flags Entertainment agreed to sell seven regional amusement parks to EPR Properties, with proceeds earmarked to reduce debt and refocus on core assets. The transaction marks a shift in how the company plans to allocate capital across its park portfolio following its merger with Cedar Fair. Management has indicated that the sale is intended to address balance sheet concerns and simplify operations after integration challenges and pressure from activist investors. For investors tracking...
XTRA:CBK
XTRA:CBKBanks

Commerzbank (XTRA:CBK) Valuation Check After Recent Pullback And Digital Growth Narrative

What Commerzbank’s Recent Returns Tell You Commerzbank (XTRA:CBK) has seen a mix of returns recently, including 1-day, weekly, monthly and past 3-month performance data that may prompt investors to reassess how its shares fit into their portfolio. Over the past year, the stock shows a total return figure alongside a multiyear track record, including 3-year and 5-year total return numbers. This offers context on how recent moves compare with longer-term performance. See our latest analysis for...
TSX:NGEX
TSX:NGEXMetals and Mining

A Look At NGEx Minerals (TSX:NGEX) Valuation After Lunahuasi Environmental Approval

Regulatory milestone at Lunahuasi puts NGEx Minerals (TSX:NGEX) in focus NGEx Minerals (TSX:NGEX) has secured approval of its Environmental Impact Statement in San Juan Province, Argentina, clearing the way for an exploration adit at the Lunahuasi project and more detailed underground evaluation. See our latest analysis for NGEx Minerals. That regulatory win comes after a choppy few weeks for the stock, with a 7 day share price return of 13.11% and a 30 day share price return of 5.10% against...
NYSE:REXR
NYSE:REXRIndustrial REITs

Rexford Industrial Realigns Leadership As Investors Weigh Execution And Dividend Cover

Rexford Industrial Realty (NYSE:REXR) has appointed John Nahas as Chief Operating Officer. The COO appointment is tied to the previously announced CEO transition and expands leadership responsibilities across the executive team. The move reflects an internal realignment of operational oversight at the company. Rexford Industrial Realty focuses on industrial real estate, a segment closely linked to logistics, distribution, and warehouse activity. For investors, changes in who oversees daily...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

A Look At Rhythm Pharmaceuticals (RYTM) Valuation After New Trial Data Earnings And Financing Updates

Why Rhythm Pharmaceuticals is back in focus after fresh trial data Rhythm Pharmaceuticals (RYTM) is back on investors’ radar after new positive Phase 3 TRANSCEND data for setmelanotide in acquired hypothalamic obesity, alongside advancing US and Japan regulatory filings and fresh financing moves. See our latest analysis for Rhythm Pharmaceuticals. At a share price of $93.52, Rhythm’s 1-day share price return of 2.25% and recent product and financing announcements sit against a softer 30-day...
OM:SWEC B
OM:SWEC BConstruction

Evaluating Sweco (OM:SWEC B) After Its High Profile Antarctica Infrastructure Role

Why the Antarctica project matters for Sweco (OM:SWEC B) shareholders Sweco (OM:SWEC B) has taken the role of Principal Designer for the new £100-million Discovery Building at Rothera Research Station in Antarctica, now formally opened under the UK Government’s Antarctic Infrastructure Modernisation Programme. This high profile scientific facility, commissioned by UK research bodies for the British Antarctic Survey, puts a spotlight on Sweco’s capabilities in complex, remote and...